-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

Benzinga·07/27/2026 17:06:21
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.